Neuralink logo displayed on a phone screen, a silhouette of a paper in shape of a human face and a binary code displayed on a screen are seen in this multiple exposure illustration photo taken in Krakow, Poland on December 10, 2021.
Jakub Porzycki | Nurphoto | Getty Images
Neuralink, the neurotech startup co-founded by Elon Musk, announced Thursday it has received approval from the Food and Drug Administration to conduct its first in-human clinical study.
Neuralink is building a brain implant called the Link, which aims to help patients with severe paralysis control external technologies using only neural signals. This means patients with severe degenerative diseases like ALS could eventually regain their ability to communicate with loved ones by moving cursors and typing with their minds.
“This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people,” the company wrote in a tweet.
The FDA and Neuralink did not immediately respond to CNBC’s request for comment. The extent of the approved trial is not known. Neuralink said in a tweet that patient recruitment for its clinical trial is not open yet.
Neuralink is part of the emerging brain-computer interface, or BCI, industry. A BCI is a system that deciphers brain signals and translates them into commands for external technologies. Neuralink is perhaps the best-known name in the space thanks to the high profile of Musk, who is also the CEO of Tesla, SpaceX and Twitter.
Scientists have been studying BCI technology for decades, and several companies have developed promising systems that they hope to bring to market. But receiving FDA approval for a commercial medical device is no small task — it requires companies to successfully conduct several extremely thorough rounds of testing and data safety collection.
No BCI company has managed to clinch the FDA’s final seal of approval. But by receiving the go-ahead for a study with human patients, Neuralink is one step closer to market.
Neuralink’s BCI will require patients to undergo invasive brain surgery. Its system centers around the Link, a small circular implant that processes and translates neural signals. The Link is connected to a series of thin, flexible threads inserted directly into the brain tissue where they detect neural signals.
Patients with Neuralink devices will learn to control it using the Neuralink app. Patients will then be able to control external mice and keyboards through a Bluetooth connection, according to the company’s website.
The FDA’s approval for an in-human study is a significant win for Neuralink after a series of recent hurdles at the company. In February, the U.S. Department of Transportation confirmed to CNBC that it had opened an investigation into Neuralink for allegedly packaging and transporting contaminated hardware in an unsafe manner. Reuters reported in March that the FDA had rejected Neuralink’s application for human trials, and reportedly outlined “dozens” of issues the company needed to address.
Neuralink has also come under fire from activist groups for its alleged treatment of animals. The Physician’s Committee for Responsible Medicine, which advocates against animal testing, has repeatedly called on Musk to release details about experiments on monkeys that had resulted in internal bleeding, paralysis, chronic infections, seizures, declining psychological health and death.
A representative for PCRM did not immediately respond to CNBC’s request for comment.
In addition to helping patients with paralysis, experts believe BCIs could someday help treat maladies like blindness and mental illness. Musk has expressed his intent for Neuralink to explore these future use cases, as well as potential applications for healthy people.
At a “show and tell” recruitment event late last year, Musk even claimed he plans to someday receive one of Neuralink’s implants himself.
“You could have a Neuralink device implanted right now and you wouldn’t even know,” Musk said at the time. “In fact, in one of these demos, I will.”
Ether ETFs have finally come to life this year after some started to fear they may be becoming zombie funds.
Collectively, the funds tracking the price of spot ether are on pace for their sixth consecutive week of inflows and eight positive week in the last nine, according to SoSoValue.
“What we’re seeing is institutional recalibration,” said Ben Kurland, CEO at crypto charting and research platform DYOR. “After the initial ETH ETF approval fizzled without a price pop, smart money started quietly building positions. They’re betting not on price momentum but on positioning ahead of utility unlocks like staking access, options listings, and eventually inflows from retirement platforms.”
The first year of ether ETFs, which launched in July 2024, has been characterized by weak demand. While the funds have had spikes in inflows, they’ve trailed far behind bitcoin ETFs in both inflows and investor attention – amassing about $3.9 billion in net inflows since listing versus bitcoin ETFs’ $36 billion in their first year of trading.
“With increasing acceptance of crypto on Wall Street, especially now as a means for payments and remittances, investors are being drawn to ETH ETFs,” said Chris Rhine, head of liquid active strategies at Galaxy Digital.
Additionally, he added, the CME basis on ether – or the price difference between ether futures and the spot price – is higher than that of bitcoin, giving arbitrageurs an opportunity to profit by going long on ether ETFs while shorting futures (a common trading strategy) and contributing to the uptrend in ether ETF inflows.
Stock Chart IconStock chart icon
Ether (ETH) 1 month
Despite the uptrend in inflows, the price of ether itself is negative for this month and flat over the past month.
For the year, it’s down 25% as it’s been suffering from an identity crisis fueled by uncertainty about Ethereum’s value proposition, weaker revenue since its last big technical upgrade and increasing competition from Solana. Market volatility driven by geopolitical uncertainty this year has not helped.
In March, Standard Chartered slashed its ether price target by more than half. However, the firm also said the coin could still see a turnaround this year.
Since last week’s big spike in inflows, they’ve “slowed but stayed net positive, suggesting conviction, not hype,” Kurland said. “The market looks like a heart monitor, but the buyers are treating it like a long-term infrastructure bet.”
Don’t miss these cryptocurrency insights from CNBC Pro:
A motorcycle is seen near a building of the Taiwan Semiconductor Manufacturing Company (TSMC), which is a Taiwanese multinational semiconductor contract manufacturing and design company, in Hsinchu, Taiwan, on April 16, 2025.
Daniel Ceng | Anadolu | Getty Images
Semiconductor stocks declined Friday following a report that the U.S. is weighing measures that would terminate waivers allowing some chipmakers to send American technology to China.
Commerce Department official Jeffrey Kessler told Samsung Electronics, SK Hynix and Taiwan Semiconductor this week that he wanted to cancel their waivers, which allow them to send U.S. chipmaking tech to their factories in China, the Wall Street Journal reported, citing people familiar with the matter.
The latest reported move by the Commerce Department comes as the U.S. and China hold an unsteady truce over tariffs and trade, with chip controls a key sticking point.
Read more CNBC tech news
The countries agreed to the framework of a second trade agreement in London days ago after relations soured following the initial tariff pause in May.
The U.S. issued several chip export changes after the May pause that rattled relations, with China calling the rules “discriminatory.”
U.S. chipmakers have been hit with curbs over the last few years, limiting the ability to sell advanced artificial intelligence chips to China due to national security concerns.
During its earnings report last month, Nvidia said the recent export restriction on its China-bound H20 chips hindered sales by about $8 billion.
Nvidia CEO Jensen Huang told investors on an earnings call that the $50 billion market in China for AI chips is “effectively closed to U.S. industry.” During a CNBC interview in May, he called getting blocked from China’s AI market a “tremendous loss.”
When Meta CEO Mark Zuckerbergpoached Scale AI founder Alexandr Wang last week as part of a $14.3 billion investment in the artificial intelligence startup, he was apparently just getting started.
Zuckerberg’s multibillion-dollar AI hiring spree has now turned to Daniel Gross, the CEO of Ilya Sutskever’s startup Safe Superintelligence, and former GitHub CEO Nat Friedman, according to sources with knowledge of the matter.
It’s not how Zuckerberg planned for a deal to go down.
Earlier this year, sources said, Meta tried to acquire Safe Superintelligence, which was reportedly valued at $32 billion in a fundraising round in April. Sutskever, who just launched the startup a year ago, shortly after leaving OpenAI, rebuffed Meta’s efforts, as well as the company’s attempt to hire him, said the sources, who asked not to be named because the information is confidential.
Soon after those talks ended, Zuckerberg started negotiating with Gross, the sources said. In addition to his role at Safe Superintelligence, Gross runs a venture capital firm with Friedman called NFDG, their combined initials.
Both men are joining Meta as part of the transaction, and will work on products under Wang, one source said. Meta, meanwhile, will get a stake in NFDG, according to multiple sources.
The Information was first to report on Meta’s plans to hire Gross and Friedman.
Gross, Friedman and Sutskever didn’t respond to CNBC’s requests for comment.
A Meta spokesperson said the company “will share more about our superintelligence effort and the great people joining this team in the coming weeks.”
Zuckerberg’s aggressive hiring tactics escalate an AI talent war that’s reached new heights of late. Meta, Google and OpenAI, along with a host of other big companies and high-valued startups, are racing to develop the most powerful large language models, and pushing towards artificial general intelligence (AGI), or AI that’s considered equal to or greater than human intelligence.
Last week, Meta agreed to pump $14.3 billion into Scale AI to bring on Wang and a few other top engineers while getting a 49% stake in the startup.
Altman said on the latest episode of the “Uncapped” podcast, which is hosted by his brother, that Meta has tried to lure OpenAI employees by offering signing bonuses as high as $100 million, with even larger annual compensation packages. Altman said “none of our best people have decided to take them up on that.”
“I’ve heard that Meta thinks of us as their biggest competitor,” Altman said on the podcast. “Their current AI efforts have not worked as well as they have hoped and I respect being aggressive and continuing to try new things.”
Meta didn’t respond to a request for comment on Altman’s remarks.
OpenAI, for its part, has gone to similar lengths, paying about $6.5 billion to hire iPhone designer Jony Ive and to acquire his nascent devices startup io.
Elsewhere, the founders of AI startup Character.AI were recruited back to Google last year in a multibillion-dollar deal, while DeepMind co-founder Mustafa Suleyman was brought on by Microsoft in a $650 million purchase of talent from Inflection AI.
In Gross, Zuckerberg is getting a longtime entrepreneur and AI investor. Gross founded the search engine Cue, which was acquired by Apple in 2013. He was a top executive at Apple and helped lead machine learning efforts and the development of Siri. He was later a partner at startup accelerator Y Combinator, before co‑founding Safe Superintelligence alongside Sutskever.
Friedman co-founded two startups before becoming the CEO of GitHub following Microsoft’s acquisition of the code-sharing platform in 2018.
NFDG has backed Coinbase, Figma, CoreWeave, Perplexity and Character.ai over the years, according to Pitchbook. It’s unclear what happens to its investment portfolio in a Meta deal, a source said.